Merck KGaA Stock
€114.25
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | 0.310% | -1.343% | 6.300% | -26.729% | -18.146% | -32.504% | -15.316% |
| Bayer AG | 0.240% | 0.219% | 0.809% | 5.520% | 42.051% | -48.167% | -32.728% |
| Elanco Animal Health Inc. | 0.580% | 1.868% | 13.327% | 64.158% | 64.357% | 44.841% | -27.557% |
| Johnson & Johnson | 0.620% | -3.107% | 4.390% | 7.354% | 15.243% | -8.662% | 36.223% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
3 Healthcare Stocks to Buy Hand Over Fist in October
If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a